Market Closed -
Other stock markets
|
After market 03:59:59 pm | |||
25.36 EUR | -1.93% | 25.28 | -0.32% |
Apr. 04 | Revenio Group Corporation Announces Composition of Nomination and Remuneration Committee | CI |
Apr. 04 | Revenio Group Corporation Approves Dividend, Payable on April 15, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.38 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.63% | 731M | - | ||
-47.34% | 2.7B | C+ | ||
+1.74% | 1.65B | - | - | |
-14.11% | 1.44B | - | ||
+25.65% | 1.25B | B+ | ||
-14.73% | 967M | - | ||
-23.17% | 834M | - | C- | |
-18.00% | 698M | B+ | ||
+3.07% | 483M | C+ | ||
-.--% | 298M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- REG1V Stock
- Ratings Revenio Group Oyj